Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593

Minesh P. Mehta, Scott P. Tannehill, Sudeshna Adak, Linda Martin, Daniel G. Petereit, Henry Wagner Jr., John F. Fowler, David Johnson

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: To assess the feasibility, toxicity, and efficacy of hyperfractionated accelerated radiation therapy (HART) for non-small-cell lung cancer (NSCLC). Patients and Methods: Thirty patients from six institutions with stage IlIa or IIIB NSCLC were enrolled between November 1993 and August 1995. Radiation therapy (total dose, 57.6 Gy in 36 fractions) was delivered over 15 days with the use of three daily fractions with a 4- hour interval between fractions and an 8-hour interval between on-cord fields. Patients were not treated on weekends. Results: Twenty-eight patients (93%) completed radiation therapy. Treatment-related toxicities of grade 3 or greater included esophagitis in six patients and grade 3 skin reaction in three patients. The overall objective response rate was 54%, and the response rate within the radiation field was 64%. With a minimum follow-up of 19 months in surviving patients, the median survival and 1-year survival rate are 13 months and 57%, respectively. The median relapse-free survival and 1- year relapse-free survival rate are 7 months and 23%, respectively. No transverse myelitis or late toxicities of grade 4 or greater have been observed. Conclusion: HART, delivered to a total dose of 57.6 Gy over 15 total days, is practical and well tolerated. Survival appears similar to that seen with modern combined modality regimens. A phase III trial is under way.

Original languageEnglish (US)
Pages (from-to)3518-3523
Number of pages6
JournalJournal of Clinical Oncology
Volume16
Issue number11
DOIs
StatePublished - Jan 1 1998

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Survival
Survival Rate
Transverse Myelitis
Ilium
Recurrence
Esophagitis
Radiation
Skin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Mehta, Minesh P. ; Tannehill, Scott P. ; Adak, Sudeshna ; Martin, Linda ; Petereit, Daniel G. ; Wagner Jr., Henry ; Fowler, John F. ; Johnson, David. / Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer : Results of Eastern Cooperative Oncology Group 4593. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 11. pp. 3518-3523.
@article{520da4dd0ec748b69dbdd1929b8328a5,
title = "Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593",
abstract = "Purpose: To assess the feasibility, toxicity, and efficacy of hyperfractionated accelerated radiation therapy (HART) for non-small-cell lung cancer (NSCLC). Patients and Methods: Thirty patients from six institutions with stage IlIa or IIIB NSCLC were enrolled between November 1993 and August 1995. Radiation therapy (total dose, 57.6 Gy in 36 fractions) was delivered over 15 days with the use of three daily fractions with a 4- hour interval between fractions and an 8-hour interval between on-cord fields. Patients were not treated on weekends. Results: Twenty-eight patients (93{\%}) completed radiation therapy. Treatment-related toxicities of grade 3 or greater included esophagitis in six patients and grade 3 skin reaction in three patients. The overall objective response rate was 54{\%}, and the response rate within the radiation field was 64{\%}. With a minimum follow-up of 19 months in surviving patients, the median survival and 1-year survival rate are 13 months and 57{\%}, respectively. The median relapse-free survival and 1- year relapse-free survival rate are 7 months and 23{\%}, respectively. No transverse myelitis or late toxicities of grade 4 or greater have been observed. Conclusion: HART, delivered to a total dose of 57.6 Gy over 15 total days, is practical and well tolerated. Survival appears similar to that seen with modern combined modality regimens. A phase III trial is under way.",
author = "Mehta, {Minesh P.} and Tannehill, {Scott P.} and Sudeshna Adak and Linda Martin and Petereit, {Daniel G.} and {Wagner Jr.}, Henry and Fowler, {John F.} and David Johnson",
year = "1998",
month = "1",
day = "1",
doi = "10.1200/JCO.1998.16.11.3518",
language = "English (US)",
volume = "16",
pages = "3518--3523",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer : Results of Eastern Cooperative Oncology Group 4593. / Mehta, Minesh P.; Tannehill, Scott P.; Adak, Sudeshna; Martin, Linda; Petereit, Daniel G.; Wagner Jr., Henry; Fowler, John F.; Johnson, David.

In: Journal of Clinical Oncology, Vol. 16, No. 11, 01.01.1998, p. 3518-3523.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer

T2 - Results of Eastern Cooperative Oncology Group 4593

AU - Mehta, Minesh P.

AU - Tannehill, Scott P.

AU - Adak, Sudeshna

AU - Martin, Linda

AU - Petereit, Daniel G.

AU - Wagner Jr., Henry

AU - Fowler, John F.

AU - Johnson, David

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Purpose: To assess the feasibility, toxicity, and efficacy of hyperfractionated accelerated radiation therapy (HART) for non-small-cell lung cancer (NSCLC). Patients and Methods: Thirty patients from six institutions with stage IlIa or IIIB NSCLC were enrolled between November 1993 and August 1995. Radiation therapy (total dose, 57.6 Gy in 36 fractions) was delivered over 15 days with the use of three daily fractions with a 4- hour interval between fractions and an 8-hour interval between on-cord fields. Patients were not treated on weekends. Results: Twenty-eight patients (93%) completed radiation therapy. Treatment-related toxicities of grade 3 or greater included esophagitis in six patients and grade 3 skin reaction in three patients. The overall objective response rate was 54%, and the response rate within the radiation field was 64%. With a minimum follow-up of 19 months in surviving patients, the median survival and 1-year survival rate are 13 months and 57%, respectively. The median relapse-free survival and 1- year relapse-free survival rate are 7 months and 23%, respectively. No transverse myelitis or late toxicities of grade 4 or greater have been observed. Conclusion: HART, delivered to a total dose of 57.6 Gy over 15 total days, is practical and well tolerated. Survival appears similar to that seen with modern combined modality regimens. A phase III trial is under way.

AB - Purpose: To assess the feasibility, toxicity, and efficacy of hyperfractionated accelerated radiation therapy (HART) for non-small-cell lung cancer (NSCLC). Patients and Methods: Thirty patients from six institutions with stage IlIa or IIIB NSCLC were enrolled between November 1993 and August 1995. Radiation therapy (total dose, 57.6 Gy in 36 fractions) was delivered over 15 days with the use of three daily fractions with a 4- hour interval between fractions and an 8-hour interval between on-cord fields. Patients were not treated on weekends. Results: Twenty-eight patients (93%) completed radiation therapy. Treatment-related toxicities of grade 3 or greater included esophagitis in six patients and grade 3 skin reaction in three patients. The overall objective response rate was 54%, and the response rate within the radiation field was 64%. With a minimum follow-up of 19 months in surviving patients, the median survival and 1-year survival rate are 13 months and 57%, respectively. The median relapse-free survival and 1- year relapse-free survival rate are 7 months and 23%, respectively. No transverse myelitis or late toxicities of grade 4 or greater have been observed. Conclusion: HART, delivered to a total dose of 57.6 Gy over 15 total days, is practical and well tolerated. Survival appears similar to that seen with modern combined modality regimens. A phase III trial is under way.

UR - http://www.scopus.com/inward/record.url?scp=0031765167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031765167&partnerID=8YFLogxK

U2 - 10.1200/JCO.1998.16.11.3518

DO - 10.1200/JCO.1998.16.11.3518

M3 - Article

C2 - 9817269

AN - SCOPUS:0031765167

VL - 16

SP - 3518

EP - 3523

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -